PROTACs are heterobifunctional small molecules that simultaneously bind a target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target. Major progress in developing potent and specific PROTACs has recently been reported, invigorating prospects for novel PROTAC-based therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PROTACs: great opportunities for academia and industry
Signal Transduction and Targeted Therapy Open Access 24 December 2019
-
Structural basis of Cullin 2 RING E3 ligase regulation by the COP9 signalosome
Nature Communications Open Access 23 August 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
23 September 2015
In the version of this article originally published, the protein ERRα was mislabeled as BRD4 in Figure 1 and its legend, and the citation of the figure in the text was misplaced. These errors have been corrected in the HTML and PDF versions of the article.
References
Sakamoto, K.M. et al. Proc. Natl. Acad. Sci. USA 98, 8554–8559 (2001).
Buckley, D.L. & Crews, C.M. Angew. Chem. Int. Edn. Engl. 53, 2312–2330 (2014).
Buckley, D.L. et al. ACS Chem. Biol. doi:10.1021/acschembio.5b00442 (2015).
Lu, J. et al. Chem. Biol. 22, 755–763 (2015).
Winter, G.E. et al. Science 348, 1376–1381 (2015).
Zengerle, M., Chan, K.H. & Ciulli, A. ACS Chem. Biol. doi:10.1021/acschembio.5b00216 (2015).
Bondeson, D.P. et al. Nat. Chem. Biol. 11, 611–617 (2015).
Ito, T.H. et al. Science 327, 1345–1350 (2010).
Krönke, J. et al. Science 343, 301–305 (2014).
Lu, G. et al. Science 343, 305–309 (2014).
Gandhi, A.K. et al. Br. J. Haematol. 164, 811–821 (2014).
Fischer, E.S. et al. Nature 512, 49–53 (2014).
Chamberlain, P.P. et al. Nat. Struct. Mol. Biol. 21, 803–809 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J.D. is co-founder of a company (Cleave Biosciences) that is developing therapeutics based on targeting enzymes in the ubiquitin-proteasome pathway. R.J.D. also holds stock in Cleave Biosciences and serves as a consultant and member of their Scientific Advisory Board.
Rights and permissions
About this article
Cite this article
Deshaies, R. Prime time for PROTACs. Nat Chem Biol 11, 634–635 (2015). https://doi.org/10.1038/nchembio.1887
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1887
This article is cited by
-
Generation of a live attenuated influenza A vaccine by proteolysis targeting
Nature Biotechnology (2022)
-
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
Acta Pharmacologica Sinica (2020)
-
Biological roles of LSD1 beyond its demethylase activity
Cellular and Molecular Life Sciences (2020)
-
Structural basis of Cullin 2 RING E3 ligase regulation by the COP9 signalosome
Nature Communications (2019)
-
PROTACs: great opportunities for academia and industry
Signal Transduction and Targeted Therapy (2019)